Lantheus (NASDAQ:LNTH) Shares Down 5.7% – Should You Sell?

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s stock price dropped 5.7% during mid-day trading on Monday . The stock traded as low as $103.92 and last traded at $103.5780. 478,643 shares were traded during trading, a decline of 50% from the average daily volume of 960,882 shares. The stock had previously closed at $109.89.

Wall Street Analysts Forecast Growth

LNTH has been the subject of several research reports. The Goldman Sachs Group reissued a “neutral” rating and issued a $94.00 target price on shares of Lantheus in a research note on Thursday, May 7th. Truist Financial reiterated a “buy” rating and issued a $115.00 price objective (up from $98.00) on shares of Lantheus in a research report on Monday, May 11th. William Blair restated an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $110.00 price objective on shares of Lantheus in a report on Tuesday, March 17th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $101.86.

Lantheus Stock Up 3.2%

The firm has a market cap of $6.95 billion, a P/E ratio of 25.72 and a beta of -0.06. The firm’s 50 day moving average is $99.32 and its two-hundred day moving average is $82.16. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The company had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. During the same period last year, the business posted $1.53 earnings per share. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, research analysts anticipate that Lantheus Holdings, Inc. will post 4.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently bought and sold shares of LNTH. EverSource Wealth Advisors LLC grew its stake in shares of Lantheus by 190.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock worth $87,000 after acquiring an additional 698 shares in the last quarter. First Trust Advisors LP grew its position in Lantheus by 37.4% in the second quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock valued at $5,714,000 after purchasing an additional 19,008 shares in the last quarter. Baird Financial Group Inc. increased its stake in Lantheus by 22.6% in the 2nd quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider’s stock valued at $222,000 after buying an additional 500 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in Lantheus by 88.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,396 shares of the medical equipment provider’s stock worth $278,000 after buying an additional 1,591 shares in the last quarter. Finally, Osterweis Capital Management Inc. acquired a new position in shares of Lantheus during the 2nd quarter worth about $36,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.